Glenmark launches Olanzapine for Injection in USA

6 Jul 2026via NSE FilingSource

English हिंदी తెలుగు தமிழ்ಕನ್ನಡ मराठी বাংলা ગુજરાતી

Glenmark launches Olanzapine for Injection in USA — Glenmark Pharmaceuticals Inc., USA has launched Olanzapine for Injection, 10 mg/vial, a single-dose vial. The product is indicated for schizophrenia and bipolar disorder. This launch expands Glenmark’s presence in the U.S. generics market. 📊 STOCKS: GLENMARK | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #ProductLaunch

#ProductLaunch#USA#Glenmark

Stocks mentioned

GLENMARKGLENMARK

⚠️ This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.

Trade smarter on NSE

Live option chains, FII flows, PCR, AI analysis — for NIFTY, BANKNIFTY & 200+ F&O stocks.

Start for ₹1 →